Welcome to our dedicated page for Seer SEC filings (Ticker: SEER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Seer, Inc.'s SEC filings document material events, operating results, securityholder rights and governance matters for a Nasdaq-listed life sciences company focused on research-use proteomics. Recent 8-K reports cover results of operations and financial condition, material definitive agreements, modifications to securityholder rights, other events and related exhibits.
The filings disclose Seer's Class A common stock, Preferred Stock Purchase Rights, Tax Benefit Preservation Plan for net operating loss and other tax attributes, amendments to that plan, and the completed conversion of Class B common stock into Class A common stock. They also record board and shareholder matters, leadership appointments, and intellectual-property updates related to the Proteograph Product Suite and particle-based protein enrichment.
Seer, Inc. reporting shows the Radoff Family Foundation directly owns 190,000 Class A shares and a Charitable Account holds 30,000 shares. Bradley L. Radoff is reported as directly owning 1,179,422 shares in Item 4, and when combined with the Foundation and Charitable Account holdings he is associated with 1,399,422 shares, representing approximately 2.6% of Seer’s ~54.8 million outstanding Class A shares. The filing indicates Mr. Radoff has sole voting and dispositive power over the majority of his direct holdings and shared power over the 190,000 Foundation shares.
The document contains an apparent inconsistency: the cover page lists sole voting/dispositive power as 1,209,422 for Mr. Radoff while Item 4 reports 1,179,422 directly owned shares; the filing does not reconcile this difference.